化学
连接器
肽
变构调节
生物化学
药物发现
激酶
氨基酸
肽序列
合理设计
结合位点
肽库
结构母题
结构-活动关系
铅化合物
结合选择性
药物设计
立体化学
酶
蛋白激酶A
血浆蛋白结合
化学生物学
计算生物学
序列母题
活动站点
环肽
分子模型
酶抑制剂
序列(生物学)
小分子
拟肽
组合化学
作者
Sara Haslböck,Alexander A. Vinogradov,Chikako Okada,Naoakusa Fujimura,Haruo Aikawa,Toru Sengoku,Hiroaki Suga
摘要
High Resolution Image Download MS PowerPoint Slide De novo discovery of highly selective inhibitors of protein kinases (PKs) remains a significant challenge in drug discovery. Although ATP-site-directed bivalent inhibitors targeting a distinct binding site are an emerging alternative, their rational design is impeded by limited knowledge about allosteric binding sites unique to the target kinase and the complexity of the linker design. Here, we report a strategy that overcomes the above-mentioned issue using a macrocyclic peptide library containing an ATP-mimetic “warhead” amino acid, p -(pyrimidin-2-ylamino)phenylalanine (termed Z), performing the RaPID selection for the discovery of highly potent and selective inhibitors against the kinase GSK3β. The experiment led to the enrichment of macrocycles containing a sequence motif “ZRZ”, whose enrichment score log 2 Y was calculated for the identification of high-affinity binders by means of next-generation sequencing analysis. We identified several highly potent inhibitors, with a representative potent peptide (BiS3) showing a K D of 0.3 nM and an IC 50 of 4.8 nM against GSK3β. The X-ray structural analysis revealed the unique binding mode of the peptides with “RZ” mimicking ATP and Mg 2+ in the ATP site. Moreover, the rest of the peptide motifs engaged in multisite interactions via a substrate-competitive site and an unexpected knob-into-hole-like conformation of the macrocycle, and thus, they act as “supra-bivalent” kinase inhibitors. This unique binding mode conferred both potency and selectivity toward GSK3β. This work demonstrated that our strategy using the warhead amino acid Z is effective in obtaining specific GSK3β inhibitors, which is likely expandable to other PK families.
科研通智能强力驱动
Strongly Powered by AbleSci AI